164 related articles for article (PubMed ID: 34656177)
1. Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling.
Filip T; Mairinger S; Neddens J; Sauberer M; Flunkert S; Stanek J; Wanek T; Okamura N; Langer O; Hutter-Paier B; Kuntner C
Alzheimers Res Ther; 2021 Oct; 13(1):175. PubMed ID: 34656177
[TBL] [Abstract][Full Text] [Related]
2. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.
Leinonen V; Rauramaa T; Johansson J; Bottelbergs A; Tesseur I; van der Ark P; Pemberton D; Koivisto AM; Jääskeläinen JE; Hiltunen M; Herukka SK; Blennow K; Zetterberg H; Jokinen P; Rokka J; Helin S; Haaparanta-Solin M; Solin O; Okamura N; Kolb HC; Rinne JO
J Alzheimers Dis; 2018; 64(1):171-179. PubMed ID: 29865068
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
[TBL] [Abstract][Full Text] [Related]
4. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
[TBL] [Abstract][Full Text] [Related]
5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
6. (S)-[
Alzghool OM; Rokka J; López-Picón FR; Snellman A; Helin JS; Okamura N; Solin O; Rinne JO; Haaparanta-Solin M
Neuropharmacology; 2021 Sep; 196():108676. PubMed ID: 34216585
[TBL] [Abstract][Full Text] [Related]
7. Tau PET With
Huang CC; Hsiao IT; Huang CY; Weng YC; Huang KL; Liu CH; Chang TY; Wu HC; Yen TC; Lin KJ
Front Neurol; 2019; 10():503. PubMed ID: 31191427
[No Abstract] [Full Text] [Related]
8. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.
Tolboom N; van der Flier WM; Yaqub M; Boellaard R; Verwey NA; Blankenstein MA; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
J Nucl Med; 2009 Sep; 50(9):1464-70. PubMed ID: 19690025
[TBL] [Abstract][Full Text] [Related]
9. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
10. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B
J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
[TBL] [Abstract][Full Text] [Related]
11. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
[TBL] [Abstract][Full Text] [Related]
12.
Meier SR; Sehlin D; Roshanbin S; Falk VL; Saito T; Saido TC; Neumann U; Rokka J; Eriksson J; Syvänen S
J Nucl Med; 2022 Feb; 63(2):302-309. PubMed ID: 34088777
[TBL] [Abstract][Full Text] [Related]
13. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology.
Harada R; Okamura N; Furumoto S; Tago T; Maruyama M; Higuchi M; Yoshikawa T; Arai H; Iwata R; Kudo Y; Yanai K
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):125-32. PubMed ID: 23100049
[TBL] [Abstract][Full Text] [Related]
15. Quantification of β-Amyloidosis and rCBF with Dedicated PET, 7 T MR Imaging, and High-Resolution Microscopic MR Imaging at 16.4 T in APP23 Mice.
Maier FC; Keller MD; Bukala D; Bender B; Mannheim JG; Brereton IM; Galloway GJ; Pichler BJ
J Nucl Med; 2015 Oct; 56(10):1593-9. PubMed ID: 26251417
[TBL] [Abstract][Full Text] [Related]
16. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
17. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Comparison of Tau Radioligands
Betthauser TJ; Lao PJ; Murali D; Barnhart TE; Furumoto S; Okamura N; Stone CK; Johnson SC; Christian BT
J Nucl Med; 2017 Jun; 58(6):996-1002. PubMed ID: 27856627
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's pathology targets distinct memory networks in the ageing brain.
Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
